BeOne Medicines (BEIGF) Amortization - Intangibles (2017 - 2024)

BeOne Medicines (BEIGF) has reported Amortization - Intangibles for 8 consecutive years, with $1.2 million the latest figure, recorded in Q2 2024.

• On a quarterly basis, Amortization - Intangibles rose 14.49% year-over-year to $1.2 million in Q2 2024; TTM through Jun 2024 was $7.6 million, a 91.06% increase from a year earlier, with the FY2023 full-year figure at $7.2 million, up 82.07% from the prior year.
• Amortization - Intangibles was $1.2 million for Q2 2024 at BeOne Medicines, down from $1.2 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $3.0 million in Q4 2023 and troughed at $187000.0 in Q3 2020.
• A 5-year average of $896444.4 and a median of $977500.0 in 2022 frame the typical range for Amortization - Intangibles.
• Across the five-year window, Amortization - Intangibles slumped 43.5% in 2020 and soared 442.55% in 2022, its largest moves.
• Over 5 years, Amortization - Intangibles stood at $188000.0 in 2020, then soared by 335.64% to $819000.0 in 2021, then increased by 18.32% to $969000.0 in 2022, then jumped by 205.16% to $3.0 million in 2023, then slumped by 60.2% to $1.2 million in 2024.
• The last three Amortization - Intangibles figures came in at $1.2 million (Q2 2024), $1.2 million (Q1 2024), and $3.0 million (Q4 2023), per Business Quant data.